BioLine RX Ltd

BioLine RX Ltd (BLRX) Stock Analysis

$1.730

-0.037 (-2.15%)At close

Loading chart…
High
1.750
Open
1.715
VWAP
1.73
Volume
7.76K
Mkt Cap
45.57M
Low
1.709
Amount
13.42K
EV/EBITDA, TTM
-0.45

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

www.biolinerx.com

AI analysis of BioLine RX Ltd (BLRX)

Sell

BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.

Analyst Ratings (4)

+593.64% upside
Buy
4 Buy
0 Hold
0 Sell
Current: 1.73
Low
12.00
Average
12.00
High
12.00

Jones Trading

2025-04-02

Price Target

—

Hold

HC Wainwright & Co.

2025-03-31

Price Target

$26

Strong Buy

HC Wainwright & Co.

2024-11-25

Price Target

$9

Strong Buy

HC Wainwright & Co.

2024-11-06

Price Target

$21

Strong Buy

Jones Trading

2024-09-04

Price Target

$2

Strong Buy
See All Ratings

Valuation Metrics

The current forward P/E ratio for BioLine RX Ltd (BLRX) is 93.46, compared to its 5-year average forward P/E of 15.21.

Forward P/E

Strongly Overvalued
5Y Average P/E
15.21
Current P/E
93.46
Overvalued
53.08
Undervalued
-22.67

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-1.03
Current EV/EBITDA
-0.45
Overvalued
0.32
Undervalued
-2.39

Forward P/S

Fair
5Y Average P/S
14.00
Current P/S
3.96
Overvalued
56.66
Undervalued
-28.65

Alphio AI Price Scenarios for BLRX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BLRX

$4.97

Scenario price

B

Base

Base · 50%BLRX

$4.62

Scenario price

B

Bear

Bear · 25%BLRX

$4.26

Scenario price

Events Timeline

2026-09-25 (ET)

17:00:00

Company Not Selling 2.02M American Depositary Shares

2026-08-31 (ET)

16:30:00

Major Averages Decline as September Rate Hike Probability Rises to 60%

12:00:00

Major Averages Broadly Lower as Oil Prices Rise

09:00:00

Investors Pull Back Amid Geopolitical and Inflation Concerns

07:30:00

BioLineRx Reports Q2 Revenue of $294,000

Show More Events

News

Show More News

BLRX FAQ — answered by Alphio AI

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment. It operates in the Healthcare sector.

BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.

4 analysts cover BLRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.

Community

More ↗
Share your thoughts on BLRX
POST

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading